



# Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of $\alpha$ -synuclein



Jon W. Werner-Allen<sup>a</sup>, Rodney L. Levine<sup>b,\*</sup>, Ad Bax<sup>a,\*\*</sup>

<sup>a</sup> Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, United States

<sup>b</sup> Laboratory of Biochemistry, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, United States

## ARTICLE INFO

### Article history:

Received 7 April 2017

Accepted 11 April 2017

Available online 12 April 2017

### Chemical compounds studied in this article:

3,4-dihydroxyphenylacetaldehyde

(PubChem CID: 119219)

### Keywords:

Parkinson's disease

Amyloid disease

Oxidative stress

Reactive oxygen species

Covalent crosslinking

Mitochondrial impairment

## ABSTRACT

Parkinson's disease has long been associated with redox imbalance and oxidative stress in dopaminergic neurons. The catecholaldehyde hypothesis proposes that 3,4-dihydroxyphenylacetaldehyde (DOPAL), an obligate product of dopamine catabolism, is a central nexus in a network of pathways leading to disease-state neurodegeneration, owing to its toxicity and potent ability to oligomerize  $\alpha$ -synuclein, the main component of protein aggregates in Lewy bodies. In this work we examine the connection between reactive oxygen species and DOPAL autoxidation. We show that superoxide propagates a chain reaction oxidation, and that this reaction is dramatically inhibited by superoxide dismutase. Moreover, superoxide dismutase prevents DOPAL from forming dicatechol pyrrole adducts with lysine and from covalently crosslinking  $\alpha$ -synuclein. Given that superoxide is a major radical byproduct of impaired cellular respiration, our results provide a possible mechanistic link between mitochondrial dysfunction and synuclein aggregation in dopaminergic neurons.

Published by Elsevier Inc.

## 1. Introduction

Parkinson's disease (PD) is an incurable neurological disorder that affects the motor system and is associated with both environmental and genetic risk factors. Its symptoms are caused by the selective loss of dopaminergic neurons in the substantia nigra region of the brain. A second, well-established pathological characteristic is the appearance in those neurons of Lewy bodies, proteinaceous aggregates that contain large amounts of the 140-residue, intrinsically disordered protein  $\alpha$ -synuclein. Genetic mutations of  $\alpha$ -synuclein also lead to early-onset forms of the disease, and these two involvements in PD have prompted extensive research into its physiological role and biophysical properties [1]. The triggers of its aggregation in the disease state remain unclear,

but an emerging understanding is that while the protein forms large amyloid fibrils in vitro, small oligomers may be the more toxic and etiologically relevant species [2].

According to the catecholaldehyde hypothesis, the preferential susceptibility of dopaminergic neurons in PD is the result of the misregulation of pathways that lead to aberrant levels of 3,4-dihydroxyphenylacetaldehyde [3]. 3,4-dihydroxyphenylacetaldehyde (DOPAL) is an obligate intermediate in dopamine catabolism – the product of monoamine oxidase, which converts the amine group of dopamine to an aldehyde – that helps end synaptic transmission and, along with neuromelanin synthesis [4], prevents potential oxidative stress caused by the accumulation of cytosolic dopamine [5]. DOPAL is far more chemically reactive than dopamine or its other metabolites, owing to its aldehyde group [6,7]. Aldehydes are known to form adducts with nucleophilic groups in proteins and nucleic acids, and those adducts have been associated with several diseases [8]. In the case of DOPAL, the catechol group also contributes to the reactivity of the aldehyde [6,9]. This peculiar property suggests that oxidation of the DOPAL catechol group to a semiquinone (loss of a single electron) or quinone (loss of two electrons) activates its aldehyde's reactivity [9,10]. The catecholaldehyde hypothesis is supported by the fact that DOPAL is highly toxic in vivo and in cultured neurons and leads

*Abbreviations:* Ac-Lys, N $\alpha$ -acetylated lysine; Ac-WT aS, N-terminally acetylated, wild-type  $\alpha$ -synuclein; DCPL, dicatechol pyrrole lysine; DOPAL, 3,4-dihydroxyphenylacetaldehyde; DTPA, diethylenetriaminepentaacetic acid; PBS, phosphate-buffered saline pH 7.4; PD, Parkinson's disease; ROS, reactive oxygen species; SOD, superoxide dismutase.

\* Corresponding author.

\*\* Corresponding author.

E-mail addresses: [rlevine@nih.gov](mailto:rlevine@nih.gov) (R.L. Levine), [bax@nih.gov](mailto:bax@nih.gov) (A. Bax).

to the loss of dopaminergic neurons when injected into the substantia nigra of rats [11–13]. DOPAL's neuronal toxicity is accompanied by the accumulation of oligomeric forms of  $\alpha$ -synuclein, and DOPAL also potently crosslinks  $\alpha$ -synuclein in vitro [13–15].

Like many other neurodegenerative disorders, PD is primarily a disease of senescence, suggesting that its progression is caused or exacerbated by the accumulation of oxidative stress [16]. This idea has been bolstered by the finding that small molecule inhibitors of complex I of the electron transport chain in mitochondria replicate the pathological hallmarks of PD in animals and humans [17–20]. Impaired respiration leads to the production of the superoxide anion, a reactive oxygen species (ROS) resulting from a single electron reduction of molecular oxygen. The brain is particularly susceptible to oxidative stress, owing to its high resting rate of oxygen consumption and large amounts of iron and polyunsaturated fatty acids [16]. Cellular defense against ROS includes superoxide dismutase (SOD), a metalloenzyme that catalyzes the dismutation of superoxide to either molecular oxygen or hydrogen peroxide, which cycle in concert with the oxidation state of its bound metal [21].

In the early 1970's, it was discovered that SOD inhibits the in vitro autoxidation of the catecholamine neurotransmitter epinephrine and the synthetic neurotoxin oxidopamine, also known as 6-hydroxydopamine [22,23]. This is attributable to the role of superoxide as a propagating species in a chain reaction that efficiently oxidizes the hydroxylated rings to semiquinones and quinones, whereas the initiating event, oxidation of the rings by molecular oxygen, occurs only slowly. In the presence of SOD, superoxide is produced from molecular oxygen by the initiating oxidation reaction, but is cleared by enzymatic dismutation and thus unable to further contribute to the reaction [22,23]. Remarkably, acceleration of oxidative decay by SOD was observed for the catecholaldehyde DOPAL [9]. In this study, we report that SOD acts as a potent enzymatic antioxidant for the catecholaldehyde when used at catalytic submicromolar concentrations, protecting against the production of dicatechol pyrrole lysine in reactions with DOPAL and lysine, and preventing the formation of DOPAL-mediated covalent oligomers of  $\alpha$ -synuclein.

## 2. Materials and methods

### 2.1. DOPAL autoxidation

DOPAL was purchased from VDM Biochemicals and stocks were prepared in deuterated methanol and quantified as described previously [10]. Autoxidation studies were performed at 37 °C in phosphate-buffered saline pH 7.4 (PBS, KD Medical) with 100  $\mu$ M DOPAL, 100  $\mu$ M diethylenetriaminepentaacetic acid (DTPA, Sigma-Aldrich) to chelate any contaminating metals – including adventitious copper that is known to be present in SOD preparations [24] – and 10% D<sub>2</sub>O. Spectra were collected on a 600 MHz Bruker Avance III spectrometer. Each 1D <sup>1</sup>H NMR spectrum was collected with 292 scans, a signal acquisition time of 2.0 s, and a 9.97 s recycle delay, for a total data collection time of 1 h.

Stocks of SOD1 from bovine erythrocytes (Sigma-Aldrich, product #: S7571) were prepared in PBS at 0.5 mg/ml, which corresponds to 15.4  $\mu$ M of the active, dimeric form of the enzyme, and diluted to a working concentration of 50 nM in the reactions. Control reactions with inactivated SOD were heated at 95 °C for 5 min, then cooled to 37 °C prior to addition of DOPAL. Stocks of catalase (Sigma-Aldrich, product #: C9322) were prepared in PBS at 1 mg/ml, or 4.0  $\mu$ M of the active, tetrameric enzyme, and diluted to a working concentration of 50 nM. Hydrogen peroxide was purchased from Sigma-Aldrich (product #: 88597).

Assays with variable SOD concentrations replicated the

conditions of Anderson *et al* [9]. Samples were prepared with 500  $\mu$ M DOPAL in 50 mM sodium phosphate buffer at pH 7.8 with 100  $\mu$ M DTPA, and samples for NMR included 10% D<sub>2</sub>O. Stocks of SOD1 were prepared in this same buffer at a concentration of 5 mg/ml (154  $\mu$ M) and diluted to the indicated working concentrations. Absorbance at 400 nm was monitored on a Cary 8454 UV–Vis spectrophotometer (Agilent) with the sample temperature maintained at 37 °C in a Peltier cell. Samples were blanked immediately prior to DOPAL addition, and spectra were recorded at three minute intervals without baseline correction. NMR data collection and DOPAL quantification were performed as described above for samples in PBS.

### 2.2. Lysyl adduct formation

Reactions with 2 mM DOPAL, 1.5 mM N $\alpha$ -acetylated lysine (Sigma-Aldrich), and 100  $\mu$ M DTPA were set up in PBS with 10% D<sub>2</sub>O and incubated at 37 °C in a 500 MHz Bruker Avance III spectrometer. A 4 h time course was measured by collecting 1D <sup>1</sup>H spectra with 142 scans, a signal acquisition time of 2.0 s, and a recycle delay of 3.97 s (15 min per spectrum). Diccatechol pyrrole lysine concentrations were calculated by integration of the well-resolved acetyl methyl signal and assigned to the midpoint of each measurement time [10]. Stocks of SOD1 from bovine erythrocytes were prepared at 5 mg/ml in PBS and diluted to a working concentration of 0.5  $\mu$ M in the reactions. SOD was inactivated by heat treatment at 95 °C for 5 min prior to the addition of DOPAL. For reactions performed with ascorbate (Sigma-Aldrich) and 5,5-dimethyl-1-pyrroline N-oxide (Sigma-Aldrich), stocks were made in PBS at concentrations of 100 mM and 1 M, respectively, and diluted to 10 mM in the assay.

### 2.3. Protein crosslinking


N-terminally acetylated wild-type  $\alpha$ -synuclein (Ac-WT aS) was obtained by bacterial co-expression of a codon-optimized synuclein construct and the NatB acetyltransferase [25,26]. The protein was expressed and purified as described previously [10]. Reactions contained 2 mM DOPAL, 100  $\mu$ M Ac-WT aS, and 100  $\mu$ M DTPA in PBS, and SOD was added at a 0.5  $\mu$ M working concentration. The reactions were incubated at 37 °C in the dark, and aliquots were drawn at the indicated times and subjected to SDS-PAGE on 1.5 mm NuPAGE 4–12% Bis-Tris gels (Invitrogen). Gels were stained with InstantBlue (Expedeon) and protein bands were detected at 700 nm on an Odyssey scanner (LI-COR Biosciences).

## 3. Results

### 3.1. Superoxide stimulates DOPAL autoxidation

To study its autoxidation, we incubated samples of 100  $\mu$ M DOPAL in PBS and followed the loss of its proton signals by 1D <sup>1</sup>H NMR (Fig. 1A). In aqueous solution, DOPAL exists in an equilibrium between the aldehyde and a hydrated, gem-diol form, with relative populations of 30% and 70%, respectively [9]. Fig. 1A illustrates the major, gem-diol signal for the DOPAL alpha protons. DOPAL is progressively oxidized over the course of the incubation, and almost entirely degraded after 12 h.

The DOPAL concentrations, determined by integration of the NMR signals, are plotted versus time in Fig. 1C. Integrals were calculated using the sum of the gem-diol and aldehyde signal intensities for the alpha protons at each time point. The alpha proton signal was found to provide a more useful measure of the DOPAL concentration than its aromatic signals, as the aromatic region of the 1D <sup>1</sup>H NMR spectrum becomes contaminated by heterogeneous breakdown products over the course of the incubation. The




**Fig. 1.** Superoxide dismutase inhibits DOPAL autoxidation. (A) The loss of DOPAL by autoxidation in H<sub>2</sub>O PBS was followed in 1D <sup>1</sup>H NMR spectra. In (A) and (B), the alpha proton signals of the major, gem-diol form of DOPAL are shown. (B) The same DOPAL signal was monitored with SOD present. (C) DOPAL concentrations were calculated based on integrated signal intensities of the alpha proton in reactions with DOPAL alone (red), with SOD (blue), and with SOD inactivated by heat treatment (gray). Reactions were performed in triplicate and error bars represent standard deviations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

integrated intensities of the alpha protons were referenced to a spectrum of 100 μM DOPAL in identical buffer that was thoroughly degassed by sonication under vacuum and the head space of its NMR tube flushed with nitrogen gas prior to acquisition in order to prevent oxidation, and the calculated DOPAL concentrations were assigned to the midpoint of each measurement time.

The effect of SOD on DOPAL autoxidation was tested by adding 50 nM of SOD1, the cytosolic form of the enzyme, from bovine erythrocytes. In contrast to the first reaction, DOPAL was very stable with SOD present, with less than 10% lost in 12 h (Fig. 1B). Comparison of the initial rates of decay in the two reactions shows that SOD inhibits the DOPAL autoxidation rate by 94%, similar to the 91% and 93% inhibition observed for epinephrine and 6-hydroxydopamine, respectively [22,23]. To verify that the inhibition of DOPAL autoxidation results from the enzymatic activity of SOD, we ran a control reaction that was heated at 95 °C for 5 min in order to inactivate the SOD, then cooled back to 37 °C prior to addition of DOPAL. In this case, the autoxidation mirrored the reaction without SOD (Fig. 1C).

The dismutation of superoxide produces hydrogen peroxide, another reactive oxygen species that may contribute to DOPAL degradation. To assess its contribution, we tested samples with 50 nM catalase, which catalyzes the decomposition of hydrogen peroxide to water and molecular oxygen. Unlike SOD, catalase failed to slow DOPAL autoxidation (Fig. S1 in the Supplementary Material). We next tested the effect of directly adding 100 μM hydrogen peroxide to the DOPAL sample. Again, there was no significant impact on the DOPAL autoxidation (Fig. S1).

The powerful inhibitory effect of SOD on DOPAL autoxidation can be explained by the reactions in Fig. 2, which are analogous to those previously proposed for epinephrine and 6-hydroxydopamine [22,23]. In reactions 1 and 2, DOPAL is converted first to a semiquinone radical and then to a quinone, in two single-electron oxidations performed by molecular oxygen. In reactions 3 and 4, these same oxidations are carried out by the superoxide radical, which is produced in reactions 1 and 2. In the presence of SOD, this superoxide is efficiently dismutated to hydrogen peroxide and molecular oxygen, such that reactions 3 and




**Fig. 2.** Reaction scheme for the oxidative decomposition of DOPAL. In reaction 1, DOPAL is oxidized by molecular oxygen to produce semiquinone and superoxide radicals. In reaction 2, the DOPAL semiquinone is oxidized again to a quinone and a second superoxide radical. In reactions 3 and 4, these same DOPAL oxidations are catalyzed by the superoxide radical. Reactions 3 and 4 are suppressed by SOD, which dismutates the superoxide produced in reactions 1 and 2. Reactions 2 and 3 comprise the propagation steps of a chain reaction in which the superoxide radical catalyzes the oxidative degradation of DOPAL.

4 do not significantly contribute to DOPAL degradation. The residual, very slow decay of DOPAL in the presence of SOD may approximate the initiating step of oxidation by molecular oxygen in reaction 1. In the absence of SOD, reactions 2 and 3 constitute the propagation steps of a superoxide-mediated chain reaction that leads to the rapid decomposition of the catecholaldehyde.

### 3.2. SOD prevents DOPAL from forming lysyl adducts

DOPAL forms adducts with proteins by reacting with the terminal sidechain amine groups of lysine residues [6,10,27]. Recently, we quantitatively characterized the adducts formed in reactions between DOPAL and either N-terminally acetylated, wild-type  $\alpha$ -synuclein (Ac-WT  $\alpha$ S) or N $\alpha$ -acetylated lysine (Ac-Lys). Under physiological conditions in reactions monitored by NMR and LC-MS, the predominant product was a dicatechol pyrrole lysine (DCPL), formed by two DOPAL molecules reacting with the lysine sidechain amine through their aldehyde moieties [10]. A surprising feature of this adduct is its pyrrole ring, which contains the lysine N $\epsilon$  and the carbons of the two DOPAL alkyl chains, and requires the formation of a carbon-carbon bond between the aldehyde-adjacent DOPAL carbons.

To determine how superoxide-mediated autoxidation affects DOPAL reactivity, we followed the production of DCPL in reactions with 2 mM DOPAL and 1.5 mM Ac-Lys in PBS at 37 °C by 1D <sup>1</sup>H NMR (Fig. 3). Without SOD, DCPL is formed at a fast and linear initial rate, followed by a plateauing at later time points, as observed previously [10]. The addition of SOD dramatically reduces the rate of DCPL formation, and this effect is again reversed by inactivation of the SOD by heat treatment. Comparing the initial, linear rates of




**Fig. 3.** Superoxide dismutase slows dicatechol pyrrole lysine formation. The DCPL concentration was followed by integrated signal intensities in 1D <sup>1</sup>H NMR spectra for reactions between Ac-Lys and DOPAL alone (red), with SOD (blue), and with SOD inactivated by heat treatment (gray). Concentrations are averaged over three independent replicates with error bars representing standard deviations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

product formation in the reactions with and without SOD shows that the enzyme inhibits DCPL production by 95%, very close to the value observed for the SOD-based inhibition of DOPAL autoxidation (94%). DCPL formation is also inhibited by addition of the radical scavenger ascorbate (Fig. S2 in the Supplementary Material), whereas 5,5-dimethyl-1-pyrroline N-oxide (DMPO), which has a rate constant toward superoxide that is  $\sim 10^7$  times lower than ascorbate [28,29], has no effect (Fig. S2).

### 3.3. SOD inhibits DOPAL-mediated $\alpha$ -synuclein crosslinking in vitro

DOPAL covalently crosslinks  $\alpha$ -synuclein in vitro and in neuronal cells, and this capability underlies its central role in the catecholaldehyde hypothesis for PD neurodegeneration [3]. We next assessed the impact of SOD on this crosslinking by setting up reactions with 2 mM DOPAL and 100  $\mu$ M Ac-WT  $\alpha$ S in PBS at 37 °C and following oligomer formation by SDS-PAGE (Fig. 4). In the absence of SOD, robust formation of protein oligomers was observed over the course of 4 h (Fig. 4A). In contrast, addition of 0.5  $\mu$ M SOD nearly completely prevented oligomer formation (Fig. 4A). Again, heat treatment of the reaction prior to DOPAL addition reversed the effect, implicating the SOD enzymatic activity as the inhibitory agent (Fig. 4B). Disulfide formation does not contribute to DOPAL-induced crosslinking of  $\alpha$ -synuclein, as the protein does not contain cysteine.



**Fig. 4.** Superoxide dismutase inhibits DOPAL-mediated  $\alpha$ -synuclein crosslinking. (A) DOPAL was incubated with N-terminally acetylated  $\alpha$ -synuclein and the formation of covalent oligomers was monitored by SDS-PAGE. Addition of SOD drastically reduced crosslinking. (B) The reactions in (A) were repeated but with the SOD inactivated by heating, which restored the crosslinking potency of DOPAL.

### 3.4. DOPAL oxidation at high SOD concentrations

A prior study reported that high concentrations of SOD stimulated DOPAL oxidation [9], as measured by the absorbance of light at 400 nm. We were able to replicate these observations (Fig. S3A in the Supplementary Material); however, we also found that the UV–Vis spectra were extensively impacted by light scattering (Fig. S3B), which hindered further analysis. Instead, we again tracked the decay of DOPAL by 1D  $^1$ H NMR spectra (Fig. S3C). The autoxidation of DOPAL is faster than in PBS due to the higher pH used by Anderson et al. (7.8 vs 7.4). As expected, addition of 50 nM SOD effectively inhibited DOPAL autoxidation. However, at higher concentrations of SOD, the rate of DOPAL decay increased, and at the highest SOD concentration measured here (40  $\mu$ M of the active enzyme, or 80  $\mu$ M of monomeric SOD), the oxidation rate exceeded the rate of native autoxidation (Fig. S3C). We considered the fact that SOD is known to produce oxygen radicals using hydrogen peroxide as a substrate [30,31], but this explanation was discounted, as in reactions with 20  $\mu$ M SOD, the addition of 500  $\mu$ M hydrogen peroxide did not accelerate DOPAL oxidation nor did the addition of 1  $\mu$ M catalase inhibit DOPAL oxidation (data not shown).

SOD has remarkable catalytic efficiency, with a reaction rate towards superoxide that is diffusion limited. Evaluating the role of superoxide in an in vitro system – as done here and elsewhere [22,23] – requires only minute concentrations of SOD to achieve maximal enzymatic clearance of the superoxide radical. The stimulation of DOPAL oxidation observed at high SOD concentrations likely results from an undescribed secondary SOD activity that competes with the protective effect of superoxide dismutation.

## 4. Discussion

The role of superoxide as a propagating species in the autoxidation of catechol-bearing compounds is well established [22,23]. Here, we extend this observation to DOPAL, an obligate intermediate of dopamine catabolism and a highly reactive toxin unique to dopaminergic neurons that crosslinks  $\alpha$ -synuclein in those cells. More interestingly, our results make it clear that DOPAL oxidation is a critical driver of its reactivity toward proteins and its ability to covalently crosslink them. This finding explains prior work by Doorn et al. demonstrating that the DOPAL catechol group activates the reactivity of its aldehyde [6], and lends support to the mechanism proposed for the formation of DCPL adducts, in which a critical step is the oxidation of the DOPAL catechol ring to a quinone and isomerization to a quinone methide, in order to activate the aldehyde-adjacent carbon for nucleophilic attack by a second DOPAL molecule [10]. It is also consistent with previous reports that DOPAL reactivity is inhibited by the radical scavenger ascorbate and other antioxidants [6,27].

Despite increasing amounts of circumstantial evidence linking PD etiology to mitochondrial dysfunction and oxidative stress, a direct mechanistic connection to  $\alpha$ -synuclein aggregation has proven elusive [32]. Recently, it was reported that certain post-translationally-modified forms of  $\alpha$ -synuclein – including small, covalent oligomers – can bind to and disrupt the mitochondrial protein import machinery, causing impaired respiration and inducing oxidative stress [33]. Such a pathway highlights the fact that DOPAL-mediated  $\alpha$ -synuclein oligomers could both initiate PD mechanisms and result from them. Given that superoxide is a major product of impaired mitochondrial respiration, our results suggest a possible connection to synuclein oligomerization, mediated by DOPAL and thus specific to dopaminergic neurons, that warrants further study in biological systems.

## Acknowledgements

We thank Daniel Mulvihill (University of Kent) for the NatB acetyltransferase construct, Yunden Jinsmaa and David Goldstein (National Institute of Neurological Disorders and Stroke) for helpful discussions and preliminary experimental work, and Sarah Monti (National Heart, Lung, and Blood Institute) for insightful comments. This work was supported by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases (ZIA DK029047-10) and the National Heart, Lung, and Blood Institute (ZIA HL000225).

## Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.bbrc.2017.04.050>.

## Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.bbrc.2017.04.050>.

## References

- [1] H.A. Lashuel, C.R. Overk, A. Oueslati, E. Masliah, The many faces of alpha-synuclein: from structure and toxicity to therapeutic target, *Nat. Rev. Neurosci.* 14 (2013) 38–48.
- [2] B. Winner, R. Jappelli, S.K. Maji, P.A. Desplats, L. Boyer, S. Aigner, C. Hetzer, T. Lohr, M. Vilar, S. Campioni, C. Tzitzilioni, A. Soragni, S. Jessberger, H. Mira, A. Consiglio, E. Pham, E. Masliah, F.H. Gage, R. Riek, In vivo demonstration that alpha-synuclein oligomers are toxic, *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 4194–4199.
- [3] D.S. Goldstein, I.J. Kopin, Y. Sharabi, Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders, *Pharmacol. Ther.* 144 (2014) 268–282.
- [4] D. Sulzer, J. Bogulavsky, K.E. Larsen, G. Behr, E. Karatekin, M.H. Kleinman, N. Turro, D. Krantz, R.H. Edwards, L.A. Greene, L. Zecca, Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles, *Proc. Natl. Acad. Sci. U. S. A.* 97 (2000) 11869–11874.
- [5] W.J. Burke, S.W. Li, H.D. Chung, D.A. Ruggiero, B.S. Kristal, E.M. Johnson, P. Lampe, V.B. Kumar, M. Franko, E.A. Williams, D.S. Zahm, Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases, *Neurotoxicology* 25 (2004) 101–115.
- [6] J.N. Rees, V.R. Florang, L.L. Eckert, J.A. Doorn, Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol, *Chem. Res. Toxicol.* 22 (2009) 1256–1263.
- [7] J.N. Rees, V.R. Florang, D.G. Anderson, J.A. Doorn, Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate, *Chem. Res. Toxicol.* 20 (2007) 1536–1542.
- [8] A. Negre-Salvayre, C. Coatrieux, C. Ingueneau, R. Salvayre, Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors, *Br. J. Pharmacol.* 153 (2008) 6–20.
- [9] D.G. Anderson, S.V. Mariappan, G.R. Buettner, J.A. Doorn, Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone, *J. Biol. Chem.* 286 (2011) 26978–26986.
- [10] J.W. Werner-Allen, J.F. DuMond, R.L. Levine, A. Bax, Toxic dopamine metabolite DOPAL forms an unexpected dicatechol pyrrole adduct with lysines of alpha-synuclein, *Angew. Chem. Int. Ed. Engl.* 55 (2016) 7374–7378.
- [11] M.B. Mattammal, J.H. Haring, H.D. Chung, G. Raghur, R. Strong, An endogenous dopaminergic neurotoxin: implication for Parkinson's disease, *Neurodegeneration* 4 (1995) 271–281.
- [12] W.J. Burke, S.W. Li, E.A. Williams, R. Nonneman, D.S. Zahm, 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis, *Brain Res.* 989 (2003) 205–213.
- [13] D.S. Goldstein, P. Sullivan, A. Cooney, Y. Jinsmaa, R. Sullivan, D.J. Gross, C. Holmes, I.J. Kopin, Y. Sharabi, Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease, *J. Neurochem.* 123 (2012) 932–943.
- [14] Y. Jinsmaa, P. Sullivan, D. Gross, A. Cooney, Y. Sharabi, D.S. Goldstein, Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein, *Neurosci. Lett.* 569 (2014) 27–32.
- [15] W.J. Burke, V.B. Kumar, N. Pandey, W.M. Panneton, Q. Gan, M.W. Franko, M. O'Dell, S.W. Li, Y. Pan, H.D. Chung, J.E. Galvin, Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine, *Acta Neuropathol.* 115 (2008) 193–203.
- [16] S.J. Chinta, J.K. Andersen, Redox imbalance in Parkinson's disease, *Biochim. Biophys. Acta* 1780 (2008) 1362–1367.
- [17] R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, J.T. Greenamyre, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, *Nat. Neurosci.* 3 (2000) 1301–1306.
- [18] J.W. Langston, P. Ballard, Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease, *Can. J. Neurol. Sci.* 11 (1984) 160–165.
- [19] F. Fornai, O.M. Schluter, P. Lenzi, M. Gesi, R. Ruffoli, M. Ferrucci, G. Lazzeri, C.L. Busceti, F. Pontarelli, G. Battaglia, A. Pellegrini, F. Nicoletti, S. Ruggieri, A. Paparelli, T.C. Sudhof, Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein, *Proc. Natl. Acad. Sci. U. S. A.* 102 (2005) 3413–3418.
- [20] C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, M. Korell, C. Marras, G.S. Bhudhikanok, M. Kasten, A.R. Chade, K. Comyns, M.B. Richards, C. Meng, B. Priestley, H.H. Fernandez, F. Cambi, D.M. Umbach, A. Blair, D.P. Sandler, J.W. Langston, Rotenone, paraquat, and Parkinson's disease, *Environ. Health Perspect.* 119 (2011) 866–872.
- [21] J.M. McCord, I. Fridovich, Superoxide dismutase. An enzymic function for erythrocyte hemocuprein, *J. Biol. Chem.* 244 (1969) 6049–6055.
- [22] H.P. Misra, I. Fridovich, The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase, *J. Biol. Chem.* 247 (1972) 3170–3175.
- [23] R.E. Heikkilä, G. Cohen, 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate, *Science* 181 (1973) 456–457.
- [24] S. Goldstein, I. Fridovich, G. Czapski, Kinetic properties of Cu,Zn-superoxide dismutase as a function of metal content—order restored, *Free Radic. Biol. Med.* 41 (2006) 937–941.
- [25] M. Johnson, A.T. Coulton, M.A. Geeves, D.P. Mulvihill, Targeted amino-terminal acetylation of recombinant proteins in *E. coli*, *PLoS One* 5 (2010) e15801.
- [26] M. Masuda, N. Dohmae, T. Nonaka, T. Oikawa, S. Hisanaga, M. Goedert, M. Hasegawa, Cysteine misincorporation in bacterially expressed human alpha-synuclein, *FEBS Lett.* 580 (2006) 1775–1779.
- [27] C. Follmer, E. Coelho-Cerqueira, D.Y. Yatabe-Franco, G.D. Araujo, A.S. Pinheiro, G.B. Domont, D. Eliezer, Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), *J. Biol. Chem.* 290 (2015) 27660–27679.
- [28] E. Finkelstein, G.M. Rosen, E.J. Rauckman, Spin trapping. Kinetics of the reaction of superoxide and hydroxyl radicals with nitrones, *J. Am. Chem. Soc.* 102 (1980) 4994–4999.
- [29] A. Nandi, I.B. Chatterjee, Scavenging of superoxide radical by ascorbic acid, *J. Biosci.* 11 (1987) 435–441.
- [30] D.C. Ramirez, S.E. Gomez-Mejiba, J.T. Corbett, L.J. Deterding, K.B. Tomer, R.P. Mason, Cu,Zn-superoxide dismutase-driven free radical modifications: copper- and carbonate radical anion-initiated protein radical chemistry, *Biochem. J.* 417 (2009) 341–353.
- [31] M.B. Yim, P.B. Chock, E.R. Stadtman, Copper, zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide, *Proc. Natl. Acad. Sci. U. S. A.* 87 (1990) 5006–5010.
- [32] M. Zaltieri, F. Longhena, M. Pizzi, C. Missale, P. Spano, A. Bellucci, Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson's disease: who's on first? *Park. Dis.* (2015) 108029, 2015.
- [33] R. Di Maio, P.J. Barrett, E.K. Hoffman, C.W. Barrett, A. Zharikov, A. Borah, X. Hu, J. McCoy, C.T. Chu, E.A. Burton, T.G. Hastings, J.T. Greenamyre, alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease, *Sci. Transl. Med.* 8 (2016), 342ra378.